These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2738937)

  • 1. Effects of tamoxifen on spinal bone density in women with breast cancer.
    Turken S; Siris E; Seldin D; Flaster E; Hyman G; Lindsay R
    J Natl Cancer Inst; 1989 Jul; 81(14):1086-8. PubMed ID: 2738937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
    Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
    Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years.
    Love RR; Mazess RB; Tormey DC; Barden HS; Newcomb PA; Jordan VC
    Breast Cancer Res Treat; 1988 Dec; 12(3):297-302. PubMed ID: 3228591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer.
    Zidan J; Keidar Z; Basher W; Israel O
    Med Oncol; 2004; 21(2):117-21. PubMed ID: 15299183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women.
    Fornander T; Rutqvist LE; Sjöberg HE; Blomqvist L; Mattsson A; Glas U
    J Clin Oncol; 1990 Jun; 8(6):1019-24. PubMed ID: 2189951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
    Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
    Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
    Jones S; Stokoe C; Sborov M; Braun M; Ethirajan S; Kutteh L; Pippen J; Patel M; Paul D; Blum JL; Holmes FA; Myron MC; Cantrell J; Hartung NL; Look RM; Di Salle E; Davis JC; Ilegbodu D; Asmar L
    Clin Breast Cancer; 2008 Dec; 8(6):527-32. PubMed ID: 19073509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
    Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
    Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone health in urban midlife Malaysian women: risk factors and prevention.
    Lim PS; Ong FB; Adeeb N; Seri SS; Noor-Aini MY; Shamsuddin K; Hapizah N; Mohamed AL; Mokhtar A; Wan HW
    Osteoporos Int; 2005 Dec; 16(12):2069-79. PubMed ID: 16234999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.
    Kristensen B; Ejlertsen B; Dalgaard P; Larsen L; Holmegaard SN; Transbøl I; Mouridsen HT
    J Clin Oncol; 1994 May; 12(5):992-7. PubMed ID: 8164053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
    Marttunen MB; Hietanen P; Tiitinen A; Ylikorkala O
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1158-62. PubMed ID: 9543133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
    Gonnelli S; Cadirni A; Caffarelli C; Petrioli R; Montagnani A; Franci MB; Lucani B; Francini G; Nuti R
    Bone; 2007 Jan; 40(1):205-10. PubMed ID: 16904960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer.
    Gotfredsen A; Christiansen C; Palshof T
    Cancer; 1984 Feb; 53(4):853-7. PubMed ID: 6692287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: preliminary study.
    Ryan WG; Wolter J; Bagdade JD
    Osteoporos Int; 1991 Oct; 2(1):39-41. PubMed ID: 1790419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
    Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
    Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
    Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB
    Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
    Vehmanen L; Elomaa I; Blomqvist C; Saarto T
    J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.